Načítá se...
The expanding role of venetoclax in chronic lymphocytic leukemia and small lymphocytic lymphoma
The BCL-2 protein family members inhibit cellular apoptosis, and their overexpression represents a common survival adaption in cancer. Recently, a selective BCL-2 inhibitor ABT-199, venetoclax, has demonstrated remarkable activity in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic...
Uloženo v:
| Vydáno v: | Blood Lymphat Cancer |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Dove
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6859801/ https://ncbi.nlm.nih.gov/pubmed/32009829 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/BLCTT.S177009 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|